Seeking to join a consortium for HORIZON-HLTH-2026-01-CARE-03: Identifying low value care

Dr. Bishal Gyawali is interested in joining a consortium for Horizon Europe Call HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems.

Dr. Bishal Gyawali, MD, PhD, FASCO, is an Ontario Institute of Cancer Research (OICR) Clinical Investigator, a medical oncologist, and an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada. His clinical expertise is across multiple adult solid tumors, with special focus on GI, GU and breast malignancies. He is in the editorial and advisory board for multiple medicine and oncology journals and has authored or co-authored more than 200 peer-reviewed articles in high-impact journals.

Dr. Gyawali has rich experience in studying value-based cancer treatments, cancer drug approval and reimbursement processes, financial and time toxicity of cancer treatments, and quality of life. He is internationally renowned in these domains of research, and serves as an expert panel member on the World Health Organization Essential Medicines List Committee, in addition to being a member of ESMO-Magnitude of Clinical Benefit Scale. Dr. Gyawali is a co-founder and co-leader of the Common Sense Oncology movement that started in 2023 and now has more than 3000 members across the world. His lab is currently planning Project De-escalate – Optimizing Clinical Benefit While Reducing Cost of Care. He has rich experience conducting high quality research on identifying low-value cancer drugs, health-technology assessment of cancer drugs, and cancer economics. In 2017, he already published probably one of the first lists of low-value practices in oncology: https://ecancer.org/en/journal...

He is happy to join consortia that are working on this goal.

For more information, or to schedule a meeting, please contact: 20cmdg@queensu.ca